Who are drug discovery’s latest movers and shakers?


There have been a number of high-level career moves within the industry in the last couple of weeks. In this update, we provide a round-up of the latest senior appointments and promotions.

Nick Maishman, ViroCell Biologics

Nick Maishman has joined contract development and manufacturing organisation ViroCell as Chief Operating Officer. The appointment follows Susan B Nichols joining the company as Chief Business Officer in September.

Maishman has previously held roles at GlaxoSmithKline, Pfizer, Valneva, Alexion and Recipharm.

Scott Curley, Amarin Pharmaceuticals Ireland

Amarin has appointed Scott Curley to its UK and Ireland team as General Manager. The company is pursuing commercial expansion following NICE’s positive recommendation for VAZKEPA (icosapent ethyl).

In his new role, Curley will initially focus on developing and growing Amarin’s organisational infrastructure for the launch of VAZKEPA. 

Ian Smith, Optibrium

Optibrium, a developer of software and AI solutions, has appointed Ian Smith as Chief Technology Officer (CTO).

Prior to this, Smith worked at Merck, Sharp and Dohme (MSD), holding positions including Director of Research and Development Analytics.

Richard White and Pardeep Sharda, The Native Antigen Company

The Native Antigen Company has expanded its management team with the addition of Richard White as Business Development Manager and Pardeep Sharda as Senior Product Manager. 

The appointments follow the company’s move to new facilities at the Oxford Technology Park.

White will be responsible for growing the company’s presence in the North American market. Sharda will focus on building and developing marketing strategies for current and new products. 

Richard Francis, Teva Pharmaceutical Industries

Teva has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. 

Francis is currently CEO of gene therapy company Purespring Therapeutics and therapeutics company Forcefield Therapeutics.

Julian Hanak, Purespring Therapeutics

Julian Hanak, Purespring’s Chief Development Officer, will take up the role of acting Chief Executive Officer.

Hanak is an experienced biopharmaceutical executive with expertise in gene therapy product development and experience across large pharma, start-ups and in the CDMO industry. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free